A total of 375 patients with a spectrum of coronary artery disease will undergo prospective , random assignment to a Orsiro Hybrid sirolimus-eluting stent or Resolute Integrity zotarolimus-eluting stent ( 2:1 ratio ) , for a primary endpoint of in-stent late lumen loss at 9 months by quantitative coronary angiography .